5 Followers on Owler
Acticor Biotech is a biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of thrombo-embolic diseases...
Read moreActicor Biotech is a biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of thrombo-embolic diseases...
Read more
Looking for similar companies to Acticor Biotech?
Acticor Biotech News
Acticor Biotech Press Releases
Acticor Biotech Videos
Acticor Biotech Headquarters
46, Henri Huchard Street Bichat Hospital - INSERM U1148
Paris, Île-de-France75018
33-970-468-640
Driving Directions »Acticor Biotech Summary
ABOUT
Overview
Acticor Biotech is a biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of thrombo-embolic diseases. Acticor Biotech was founded in 2013. Acticor Biotech's headquarters is located in Paris, Île-de-France, FR 750...CEO
Acticor Biotech's CEO, Gilles Avenard, currently has an approval rating of 85%. Acticor Biotech's primary competitors are Espero Biopharma, Breath Therapeutics, Kymab and 8 more.Website
acticor-biotech.comCompetitors
View 11 Acticor Biotech competitors here.Acquisitions
There have been no acquisitions found related to Acticor BiotechInvestments
Recent investment data cannot be found related to Acticor BiotechFrequently Asked Questions about Acticor Biotech
When was Acticor Biotech founded?
Acticor Biotech was founded in 2013Who is Acticor Biotech's CEO?
Acticor Biotech's CEO is Gilles AvenardHow much revenue does Acticor Biotech generate?
Acticor Biotech generates $2.5M in revenueHow much funding does Acticor Biotech have?
Acticor Biotech has historically raised $33.4M in funding
Where is Acticor Biotech's headquarters?
Acticor Biotech's headquarters is in Paris Île-de-France, FRHow many employees does Acticor Biotech have?
Acticor Biotech has 16 employeesWhat sector does Acticor Biotech operate in?
Acticor Biotech is in PharmaceuticalsWho are Acticor Biotech's competitors?
Acticor Biotech's top competitors are Espero Biopharma, Breath Therapeutics, Kymab